Discovery of prevalent, clinically actionable tumor neoepitopes via integrated biochemical and cell-based platforms

Abstract excerpt

<h4>Summary</h4> Strategies for maximizing the potency and specificity of cancer immunotherapies have sparked efforts to identify recurrent epitopes presented in the context of defined tumor-associated neoantigens. Discovering these “neoepitopes” can be difficult owing to the limited number of peptides that arise from a single point mutation, a low number of copies presented on the cell surface, and variable bind...

Topics

Open a Topic to create a Post that cites this publication.

• Antigens, Neoplasm
• CD4-Positive T-Lymphocytes
• CD8-Positive T-Lymphocytes
• Immunotherapy
• Immunotherapy and Immune Responses
• Mutation
• Neoplasms
• Receptors, Antigen, T-Cell

Identifiers and source

Literature Corpus work

5d7f9451-de5d-5e6c-9e04-d51d51fadff2

DOI

10.1101/2022.10.27.513529